Annual Total Expenses
$461.75 M
+$62.87 M+15.76%
31 December 2023
Summary:
Iovance Biotherapeutics annual total expenses is currently $461.75 million, with the most recent change of +$62.87 million (+15.76%) on 31 December 2023. During the last 3 years, it has risen by +$199.81 million (+76.28%). IOVA annual total expenses is now at all-time high.IOVA Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Expenses
$147.62 M
+$14.60 M+10.98%
30 September 2024
Summary:
Iovance Biotherapeutics quarterly total expenses is currently $147.62 million, with the most recent change of +$14.60 million (+10.98%) on 30 September 2024. Over the past year, it has increased by +$28.79 million (+24.23%). IOVA quarterly total expenses is now at all-time high.IOVA Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IOVA Total Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +15.8% | +24.2% |
| 3 y3 years | +76.3% | +71.2% |
| 5 y5 years | +260.0% | +186.0% |
IOVA Total Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +76.3% | at high | +71.2% |
| 5 y | 5 years | at high | +260.0% | at high | +186.0% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Iovance Biotherapeutics Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $147.62 M(+11.0%) |
| June 2024 | - | $133.02 M(+12.3%) |
| Mar 2024 | - | $118.44 M(-2.7%) |
| Dec 2023 | $461.75 M(+15.8%) | $121.74 M(+2.4%) |
| Sept 2023 | - | $118.83 M(+7.7%) |
| June 2023 | - | $110.32 M(-0.5%) |
| Mar 2023 | - | $110.86 M(+3.6%) |
| Dec 2022 | $398.88 M(+16.4%) | $107.04 M(+6.6%) |
| Sept 2022 | - | $100.39 M(+0.7%) |
| June 2022 | - | $99.73 M(+8.7%) |
| Mar 2022 | - | $91.71 M(-7.8%) |
| Dec 2021 | $342.70 M(+30.8%) | $99.47 M(+15.3%) |
| Sept 2021 | - | $86.24 M(+5.9%) |
| June 2021 | - | $81.43 M(+7.7%) |
| Mar 2021 | - | $75.57 M(+10.3%) |
| Dec 2020 | $261.94 M(+26.6%) | $68.53 M(+16.2%) |
| Sept 2020 | - | $58.97 M(-7.3%) |
| June 2020 | - | $63.63 M(-10.1%) |
| Mar 2020 | - | $70.81 M(+8.8%) |
| Dec 2019 | $206.87 M(+61.3%) | $65.11 M(+26.2%) |
| Sept 2019 | - | $51.61 M(+2.9%) |
| June 2019 | - | $50.16 M(+25.5%) |
| Mar 2019 | - | $39.99 M(+14.4%) |
| Dec 2018 | $128.26 M(+38.1%) | $34.94 M(-0.3%) |
| Sept 2018 | - | $35.06 M(+11.7%) |
| June 2018 | - | $31.38 M(+16.7%) |
| Mar 2018 | - | $26.88 M(+3.1%) |
| Dec 2017 | $92.88 M(+73.2%) | $26.07 M(+16.7%) |
| Sept 2017 | - | $22.34 M(-5.2%) |
| June 2017 | - | $23.58 M(+12.9%) |
| Mar 2017 | - | $20.88 M(+31.2%) |
| Dec 2016 | $53.64 M | $15.92 M(-16.1%) |
| Sept 2016 | - | $18.98 M(+61.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2016 | - | $11.73 M(+67.3%) |
| Mar 2016 | - | $7.01 M(-17.3%) |
| Dec 2015 | $27.86 M(+131.4%) | $8.48 M(+10.9%) |
| Sept 2015 | - | $7.64 M(+18.7%) |
| June 2015 | - | $6.44 M(+21.6%) |
| Mar 2015 | - | $5.30 M(+8.8%) |
| Dec 2014 | $12.04 M(-46.8%) | $4.87 M(+73.7%) |
| Sept 2014 | - | $2.80 M(+32.8%) |
| June 2014 | - | $2.11 M(-6.6%) |
| Mar 2014 | - | $2.26 M(-80.3%) |
| Dec 2013 | $22.64 M(+178.4%) | $11.50 M(+22.2%) |
| Sept 2013 | - | $9.41 M(+814.1%) |
| June 2013 | - | $1.03 M(+46.0%) |
| Mar 2013 | - | $704.90 K(-59.1%) |
| Dec 2012 | $8.13 M(-61.4%) | $1.72 M(+5.8%) |
| Sept 2012 | - | $1.63 M(-1.1%) |
| June 2012 | - | $1.65 M(-47.5%) |
| Mar 2012 | - | $3.14 M(-22.1%) |
| Dec 2011 | $21.06 M(+2482.6%) | $4.02 M(-30.8%) |
| Sept 2011 | - | $5.81 M(-44.9%) |
| June 2011 | - | $10.56 M(+1504.3%) |
| Mar 2011 | - | $658.30 K(+32.7%) |
| Dec 2010 | $815.40 K(+5060.8%) | $496.10 K(+197.1%) |
| Sept 2010 | - | $167.00 K(+97.4%) |
| June 2010 | - | $84.60 K(+25.0%) |
| Mar 2010 | - | $67.70 K(+2843.5%) |
| Dec 2009 | $15.80 K(-72.3%) | $2300.00(-34.3%) |
| Sept 2009 | - | $3500.00(+6.1%) |
| June 2009 | - | $3300.00(-50.0%) |
| Mar 2009 | - | $6600.00(-53.8%) |
| Dec 2008 | $57.10 K | $14.30 K(+472.0%) |
| Sept 2008 | - | $2500.00(-83.3%) |
| June 2008 | - | $15.00 K(-40.7%) |
| Mar 2008 | - | $25.30 K |
FAQ
- What is Iovance Biotherapeutics annual total expenses?
- What is the all time high annual total expenses for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics annual total expenses year-on-year change?
- What is Iovance Biotherapeutics quarterly total expenses?
- What is the all time high quarterly total expenses for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics quarterly total expenses year-on-year change?
What is Iovance Biotherapeutics annual total expenses?
The current annual total expenses of IOVA is $461.75 M
What is the all time high annual total expenses for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high annual total expenses is $461.75 M
What is Iovance Biotherapeutics annual total expenses year-on-year change?
Over the past year, IOVA annual total expenses has changed by +$62.87 M (+15.76%)
What is Iovance Biotherapeutics quarterly total expenses?
The current quarterly total expenses of IOVA is $147.62 M
What is the all time high quarterly total expenses for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high quarterly total expenses is $147.62 M
What is Iovance Biotherapeutics quarterly total expenses year-on-year change?
Over the past year, IOVA quarterly total expenses has changed by +$28.79 M (+24.23%)